Przeklasa-Muszynska, A., & Dobrogowski, J. (2011). Transdermal buprenorphine in the treatment of cancer and non-cancer pain—The results of multicenter studies in Poland. Pharmacological Reports: PR, 63(4), 935–948.
To evaluate the analgesic activity, safety of use, and safety profile of transdermal buprenorphine used in the treatment of chronic moderate to severe cancer and noncancer pain
The sample was composed of 4,030 general outpatients as well as inpatients. The study process started in 2007 and was completed in 2008. Authors applied a visual analog scale to score pain intensity and used nonserious adverse drug reaction (NON-SADR) data to measure side effects.
Nonrandomized prospective uncontrolled, open-label, single-arm postmarketing study
In this study, transdermal buprenorphine study was highly efficacious and well tolerated.
In this study, transdermal buprenorphine proved safe, effective, and easy to administer.
Use of transdermal buprenorphine will help to reduce pain but may produce adverse effects. Nurses should be knowledgeable about these effects and ready to spot and treat them. Patients should be aware of possible adverse effects prior to using transdermal buprenorphine, so they can report adverse effects promptly. To minimize adverse effects, avoid prolonged use of the drug.